Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Faldaprevir in Healthy Males
NCT02182323Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, single-blind trial of faldaprevir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with abnormal findings in physical examination up to 12 days, Number of patients with clinically significant changes in vital signs up to 12 days and 4 more. Started Sep 2006; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182323.